TACROLIMUS 0.1% OINTMENT

CLASS: Calcineurin Inhibitor; Immunosuppressant Agent; Topical Skin Product

INDICATIONS:

Moderate-to-severe atopic dermatitis in immunocompetent patients not responsive to conventional therapy or when conventional therapy is not appropriate

Canadian labeling: Additional use (not in U.S. labeling): Maintenance therapy to prevent flares and extend flare-free intervals in patients with moderate-to-severe atopic dermatitis who are responsive to initial therapy and experiencing ≥5 flares per year

AVAILABLE DOSAGE FROM THE HOSPITAL:

TACROLIMUS 0.1% OINTMENT

DOSAGE:

Atopic dermatitis (moderate-to-severe): Topical:

Treatment: Apply thin layer of 0.03% or 0.1% ointment to affected area twice daily; rub in gently and completely. Discontinue use when symptoms have cleared. If no improvement within 6 weeks, patients should be re-examined to confirm diagnosis.

Maintenance therapy (Canadian labeling; not in U.S. labeling): Apply one application (thin layer of 0.03% or 0.1% ointment) to areas usually affected twice a week, allowing 2-3 days between applications (eg, one application on Monday and Thursday). Re-evaluate after 12 months. Safety of maintenance therapy >12 months has not been established.

Note: Patients experiencing flares should resume twice daily treatment.

Geriatric

Refer to adult dosing.

COMMON SIDE EFFECT:

>10%:

Central nervous system: Headache (5% to 20%), fever (1% to 21%)

Dermatologic: Skin burning (43% to 58%; tends to improve as lesions resolve), pruritus (41% to 46%), erythema (12% to 28%)

Respiratory: Increased cough (children 18%)

Miscellaneous: Flu-like syndrome (23% to 31%), allergic reaction (4% to 12%)

PREGNANCY RISK FACTORS: C